Susquehanna International Group, LLP Cardiff Oncology, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.05 - $2.77 $57,809 - $78,114	28,200 Added 21.59%	158,800 $423,000
Q2 2024 Aug 15, 2024	BUY	$2.22 - $5.89 $68,820 - $182,590	31,000 Added 31.12%	130,600 $289,000
Q1 2024 May 07, 2024	BUY	$1.46 - $5.91 $129,502 - $524,217	88,700 Added 813.76%	99,600 $531,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $145,248 - $234,515	-151,300 Reduced 93.28%	10,900 $16,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $2.18 $223,835 - $353,596	162,200 New	162,200 $225,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $28,056 - $42,448	-5,600 Reduced 12.99%	37,500 $250,000
Q2 2021 Aug 11, 2021	BUY	$6.65 - $10.04 $63,175 - $95,379	9,500 Added 28.27%	43,100 $287,000
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $1.59 Million - $3.42 Million	-174,800 Reduced 83.88%	33,600 $311,000
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $651,484 - $1.34 Million	-54,200 Reduced 20.64%	208,400 $3.75 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $1.12 Million - $3.73 Million	262,600 New	262,600 $3.73 Million

12.4M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $195M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.